<DOC>
	<DOCNO>NCT02946359</DOCNO>
	<brief_summary>This phase II , prospective , single arm , non comparative study crizotinib combine bevacizumab treatment-naive lung adenocarcinoma cancer patient ALK translocation ROS1 translocation MET amplification</brief_summary>
	<brief_title>A+C Metastatic Lung Adenocarcinoma Cancer</brief_title>
	<detailed_description>This phase II , prospective , single arm , non comparative study crizotinib combine bevacizumab treatment-naive lung adenocarcinoma cancer patient ALK translocation ROS1 translocation MET amplification . Patients locally advance metastatic NSCLC ( Stage ⅢB/ⅢC/Ⅳ ) least one measurable tumor lesion consider eligible trial . All potentially eligible patient evaluate ALK、MET ROS1 FISH IHC NGS detect MET amplification ALK translocation ROS1 translocation After evaluation inclusion exclusion criterion , signature inform consent form , MET amplify ALK translocation ROS1 translocate eligible patient receive crizotinib 250 mg BID p.o bevacizumab 7.5mg/kg every three week disease progression , unacceptable toxicity patient refusal .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Histologically confirm diagnosis lung adenocarcinoma cancer Availability tumor tissue ROS1 , ALK , MET analyse EGFR wild type , positive ROS1 translocation ALK translocation MET amplification At least one radiological measurable disease accord RECIST criterion ( Response Evaluation Criteria Solid Tumors ) Patient n't receive therapy lung cancer except surgery radiotherapy , adjuvant chemotherapy stop 12 month Performance status 02 ( ECOG ) Patient compliance trial procedure age ≥ 18 year Written inform consent Adequate BM function ( ANC ≥ 1.5x109/L , Platelets ≥ 100x109/L , HgB &gt; 9g/dl ) Adequate liver function ( bilirubin &lt; G2 , transaminases 3xULN/ &lt; 5xULN present liver metastasis ) . Normal level alkaline phosphatase creatinine . If female : childbearing potential either terminate surgery , radiation , menopause , attenuate use approve contraceptive method [ intrauterine contraceptive device ( IUD ) , birth control pill , barrier device ] ninety ( 90 ) day end treatment . Patients EGFR mutation No tumor tissue available patient negative ALK translocation ROS1 translocation MET amplification Absence measurable lesion Prior therapy bevacizumab ipilimumab Symptomatic brain metastasis Previous radiotherapy target lesion ( ) . If site include radiotherapy field patient eligible evidence progressive disease completion radiotherapy . Diagnosis malignancy last 5 year , except situ carcinoma cervix uteri squamous cell carcinoma skin Pregnancy lactate Other serious illness medical condition potentially interfere study Significant know vascular disease Symptomatic peripheral vascular disease Evidence bleed diathesis coagulopathy Major surgical procedure significant traumatic injury within 28 day prior study enrollment Serious , nonhealing wound , ulcer bone fracture Proteinuria screen Known hypersensitivity component bevacizumab History hemoptysis within 3 month prior study enrollment Current , ongoing treatment fulldose warfarin equivalent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>